Live attenuated influenza viruses produced in a suspension process with avian AGE1.CR.pIX cells

BMC Biotechnology

Volumn 12, Issue , 2012, Pages

  Lohr, Verena ^a   Genzel, Yvonne ^a   Jordan, Ingo ^b   Katinger, Dietmar ^c   Mahr, Stefan ^a,d   Sandig, Volker ^b   Reichl, Udo ^a,e  

^a MAX PLANCK INSTITUTE FOR DYNAMICS OF COMPLEX TECHNICAL SYSTEMS   (Germany)

^b PROBIOGEN AG   (Germany)

^c Polymun Scientific GmbH   (Austria)

^d University for Applied Sciences   (Germany)

^e OTTO VON GUERICKE UNIVERSITY   (Germany)

Author keywords

AGE1.CR.pIX; Cell density effect; Influenza vaccine production; Live attenuated influenza virus; Suspension cell culture

Indexed keywords

AGE1.CR.PIX; CELL DENSITY; INFLUENZA VACCINES; INFLUENZA VIRUS; SUSPENSION CELL CULTURE;

CELL CULTURE; STRAIN; VACCINES; VIRUSES;

CELLS;

INFLUENZA VACCINE; TRYPSIN;

ARTICLE; BIOREACTOR; CELL ADHESION; CELL DENSITY; CELL VIABILITY; ENZYME ACTIVITY; INFLUENZA VIRUS A H1N1; NONHUMAN; TEMPERATURE SENSITIVITY; VACCINE PRODUCTION; VERO CELL; VIRION; VIRUS REPLICATION; VIRUS STRAIN;

ADAPTATION, PHYSIOLOGICAL; ANIMALS; BIOREACTORS; CELL CULTURE TECHNIQUES; CELL LINE; CULTURE MEDIA; DUCKS; HUMANS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA, HUMAN; TEMPERATURE; VACCINES, ATTENUATED; VIRUS CULTIVATION; VIRUS REPLICATION;

AVES; CERCOPITHECINE HERPESVIRUS 1; HUMAN INFLUENZA VIRUS; ORTHOMYXOVIRIDAE;

EID: 84867900282     PISSN: None     EISSN: 14726750     Source Type: Journal    
DOI: 10.1186/1472-6750-12-79     Document Type: Article

References (49)

1. Hancock K, Veguilla V, Lu X, Zhong W, Butler EN, Sun H, Liu F, Dong L, DeVos JR, Gargiullo PM, et al. Cross-reactive antibody responses to the 2009 pandemic H1N1 influenza virus. N Engl J Med 2009, 361(20):1945-1952. 10.1056/NEJMoa0906453, 19745214.
2. Sun K, Ye J, Perez DR, Metzger DW. Seasonal FluMist vaccination induces cross-reactive T cell immunity against H1N1 (2009) influenza and secondary bacterial infections. J Immunol 2011, 186(2):987-993. 10.4049/jimmunol.1002664, 21160043.
3. Tosh PK, Boyce TG, Poland GA. Flu myths: dispelling the myths associated with live attenuated influenza vaccine. Mayo Clinic proceedings Mayo Clinic 2008, 83(1):77-84.
4. Clements ML, Betts RF, Tierney EL, Murphy BR. Resistance of adults to challenge with influenza A wild-type virus after receiving live or inactivated virus vaccine. J Clin Microbiol 1986, 23(1):73-76. 268575, 3700611.
5. Carter NJ, Curran MP. Live attenuated influenza vaccine (FluMist(R); Fluenz): a review of its use in the prevention of seasonal influenza in children and adults. Drugs 2011, 71(12):1591-1622. 10.2165/11206860-000000000-00000, 21861544.
6. Global pandemic influenza action plan to increase vaccine supply: WHO/IVB/06.13 http://www.who.int/csr/resources/publications/influenza/WHO_CDS_EPR_GIP_2006_1/en/index.html.
7. Chen Z, Wang W, Zhou H, Suguitan AL, Shambaugh C, Kim L, Zhao J, Kemble G, Jin H. Generation of live attenuated novel influenza virus A/California/7/09 (H1N1) vaccines with high yield in embryonated chicken eggs. J Virol 2010, 84(1):44-51. 10.1128/JVI.02106-09, 2798434, 19864389.
8. Liu J, Shi X, Schwartz R, Kemble G. Use of MDCK cells for production of live attenuated influenza vaccine. Vaccine 2009, 27(46):6460-6463. 10.1016/j.vaccine.2009.06.024, 19559113.
9. Ghendon YZ, Markushin SG, Akopova II, Koptiaeva IB, Nechaeva EA, Mazurkova LA, Radaeva IF, Kolokoltseva TD. Development of cell culture (MDCK) live cold-adapted (CA) attenuated influenza vaccine. Vaccine 2005, 23(38):4678-4684. 10.1016/j.vaccine.2005.04.039, 16026905.
10. George M, Farooq M, Dang T, Cortes B, Liu J, Maranga L. Production of cell culture (MDCK) derived live attenuated influenza vaccine (LAIV) in a fully disposable platform process. Biotechnol Bioeng 2010, 106(6):906-917. 10.1002/bit.22753, 20589670.
11. Romanova J, Katinger D, Ferko B, Vcelar B, Sereinig S, Kuznetsov O, Stukova M, Erofeeva M, Kiselev O, Katinger H, et al. Live cold-adapted influenza A vaccine produced in Vero cell line. Virus Res 2004, 103(1-2):187-193.
12. Egorov A, Brandt S, Sereinig S, Romanova J, Ferko B, Katinger D, Grassauer A, Alexandrova G, Katinger H, Muster T. Transfectant influenza A viruses with long deletions in the NS1 protein grow efficiently in Vero cells. J Virol 1998, 72(8):6437-6441. 109801, 9658085.
13. Audsley JM, Tannock GA. The growth of attenuated influenza vaccine donor strains in continuous cell lines. J Virol Methods 2005, 123(2):187-193. 10.1016/j.jviromet.2004.09.015, 15620401.
14. Hussain AI, Cordeiro M, Sevilla E, Liu J. Comparison of egg and high yielding MDCK cell-derived live attenuated influenza virus for commercial production of trivalent influenza vaccine: in vitro cell susceptibility and influenza virus replication kinetics in permissive and semi-permissive cells. Vaccine 2010, 28(22):3848-3855. 10.1016/j.vaccine.2010.03.005, 20307595.
15. Chu C, Lugovtsev V, Golding H, Betenbaugh M, Shiloach J. Conversion of MDCK cell line to suspension culture by transfecting with human siat7e gene and its application for influenza virus production. Proc Natl Acad Sci USA 2009, 106(35):14802-14807. 10.1073/pnas.0905912106, 2728112, 19706449.
16. Lohr V, Genzel Y, Behrendt I, Scharfenberg K, Reichl U. A new suspension MDCK cell line cultivated in a fully defined medium in stirred-tank and wave bioreactor. Vaccine 2010, 28(38):6256-6264. 10.1016/j.vaccine.2010.07.004, 20638458.
17. Paillet C, Forno G, Kratje R, Etcheverrigaray M. Suspension-Vero cell cultures as a platform for viral vaccine production. Vaccine 2009, 27(46):6464-6467. 10.1016/j.vaccine.2009.06.020, 19559123.
18. van Wielink R, Kant-Eenbergen HC, Harmsen MM, Martens DE, Wijffels RH, Coco-Martin JM. Adaptation of a Madin-Darby canine kidney cell line to suspension growth in serum-free media and comparison of its ability to produce avian influenza virus to Vero and BHK21 cell lines. J Virol Methods 2011, 171(1):53-60. 10.1016/j.jviromet.2010.09.029, 20933017.
19. Doroshenko A, Halperin SA. Trivalent MDCK cell culture-derived influenza vaccine Optaflu (Novartis Vaccines). Expert Rev Vaccines 2009, 8(6):679-688. 10.1586/erv.09.31, 19485748.
20. Cox RJ, Madhun AS, Hauge S, Sjursen H, Major D, Kuhne M, Hoschler K, Saville M, Vogel FR, Barclay W, et al. A phase I clinical trial of a PER.C6 cell grown influenza H7 virus vaccine. Vaccine 2009, 27(13):1889-1897. 10.1016/j.vaccine.2009.01.116, 19368768.
21. Le Ru A, Jacob D, Transfiguracion J, Ansorge S, Henry O, Kamen AA. Scalable production of influenza virus in HEK-293 cells for efficient vaccine manufacturing. Vaccine 2010, 28(21):3661-3671. 10.1016/j.vaccine.2010.03.029, 20347632.
22. Brown SW, Mehtali M. The Avian EB66(R) Cell Line, Application to Vaccines, and Therapeutic Protein Production. PDA J Pharm Sci Technol / PDA 2010, 64(5):419-425.
23. Lohr V, Rath A, Genzel Y, Jordan I, Sandig V, Reichl U. New avian suspension cell lines provide production of influenza virus and MVA in serum-free media: studies on growth, metabolism and virus propagation. Vaccine 2009, 27(36):4975-4982. 10.1016/j.vaccine.2009.05.083, 19531390.
24. Jordan I, Vos A, Beilfuss S, Neubert A, Breul S, Sandig V. An avian cell line designed for production of highly attenuated viruses. Vaccine 2009, 27(5):748-756. 10.1016/j.vaccine.2008.11.066, 19071186.
25. Jordan I, Northoff S, Thiele M, Hartmann S, Horn D, Howing K, Bernhardt H, Oehmke S, von Horsten H, Rebeski D, et al. A chemically defined production process for highly attenuated poxviruses. Biologicals 2011, 39(1):50-58. 10.1016/j.biologicals.2010.11.005, 21237672.
26. Lohr V, Rath A, Jordan I, Sandig V, Genzel Y, Reichl U. Avian Designer Cells AGE1.CR as Candidates for MVA and Influenza Vaccine Production. Proceedings of the 21st Annual Meeting of the European Society for Animal Cell Technology (ESACT) 2009, 615-631. Dublin, Ireland: SpringerLink, Jenkins N, Barron N, Alves P.
27. Zhang C, Ferreira TB, Cruz PE, Alves PM, Haury M, Carrondo MJT. The importance of 293 cell cycle phase on adenovirus vector production. Enzyme Microb Technol 2006, 39:1328-1332.
28. Bernal V, Carinhas N, Yokomizo AY, Carrondo MJ, Alves PM. Cell density effect in the baculovirus-insect cells system: a quantitative analysis of energetic metabolism. Biotechnol Bioeng 2009, 104(1):162-180. 10.1002/bit.22364, 19459142.
29. Bedard C, Kamen A, Tom R, Massie B. Maximization of recombinant protein yield in the insect cell/baculovirus system by one-time addition of nutrients to high-density batch cultures. Cytotechnology 1994, 15(1-3):129-138.
30. Meghrous J, Mahmoud W, Jacob D, Chubet R, Cox M, Kamen AA. Development of a simple and high-yielding fed-batch process for the production of influenza vaccines. Vaccine 2009, 28(2):309-316. 10.1016/j.vaccine.2009.10.048, 19879996.
31. Ferreira TB, Perdigao R, Silva AC, Zhang C, Aunins JG, Carrondo MJ, Alves PM. 293 cell cycle synchronisation adenovirus vector production. Biotechnol Prog 2009, 25(1):235-243. 10.1002/btpr.64, 19199366.
32. Petiot E, Jacob D, Lanthier S, Lohr V, Ansorge S, Kamen AA. Metabolic and kinetic analyses of influenza production in perfusion HEK293 cell culture. BMC Biotechnol 2011, 11:84. 10.1186/1472-6750-11-84, 3175177, 21884612.
33. Bock A, Schulze-Horsel J, Schwarzer J, Rapp E, Genzel Y, Reichl U. High-density microcarrier cell cultures for influenza virus production. Biotechnol Prog 2011, 27(1):241-250. 10.1002/btpr.539, 21312371.
34. Moskvichyov BV, Komanov EV, Ivanova GP. Study of Trypsin Thermodenaturation Process. Enzyme Microb Technol 1986, 8(8):498-502.
35. Feng SZ, Jiao PR, Qi WB, Fan HY, Liao M. Development and strategies of cell-culture technology for influenza vaccine. Appl Microbiol Biotechnol 2011, 89(4):893-902. 10.1007/s00253-010-2973-9, 21063703.
36. Genzel Y, Reichl U. Continuous cell lines as production system for influenza vaccines. Expert Rev Vaccines 2009, 8(12):1681-1692. 10.1586/erv.09.128, 19943763.
37. Pau MG, Ophorst C, Koldijk MH, Schouten G, Mehtali M, Uytdehaag F. The human cell line PER.C6 provides a new manufacturing system for the production of influenza vaccines. Vaccine 2001, 19(17-19):2716-2721.
38. Prevention and Control of Influenza: Recommendations of the Advisory Committee on Immunization Practices (ACIP) http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5408a1.htm.
39. Solorzano A, Ye J, Perez DR. Alternative live-attenuated influenza vaccines based on modifications in the polymerase genes protect against epidemic and pandemic flu. J Virol 2010, 84(9):4587-4596. 10.1128/JVI.00101-10, 2863734, 20181702.
40. Chen Z, Aspelund A, Kemble G, Jin H. Molecular studies of temperature-sensitive replication of the cold-adapted B/Ann Arbor/1/66, the master donor virus for live attenuated influenza FluMist vaccines. Virology 2008, 380(2):354-362. 10.1016/j.virol.2008.08.010, 18804834.
41. Katinger H, Egorov A, Ferko B, Romanova J, Katinger D. Live attenuated influenza vaccine 2009, PCT/EP01/11087; US 7,494,659 B2.
42. Kiseleva I, Su Q, Toner TJ, Szymkowiak C, Kwan WS, Rudenko L, Shaw AR, Youil R. Cell-based assay for the determination of temperature sensitive and cold adapted phenotypes of influenza viruses. J Virol Methods 2004, 116(1):71-78. 10.1016/j.jviromet.2003.10.012, 14715309.
43. Chan W, Zhou H, Kemble G, Jin H. The cold adapted and temperature sensitive influenza A/Ann Arbor/6/60 virus, the master donor virus for live attenuated influenza vaccines, has multiple defects in replication at the restrictive temperature. Virology 2008, 380(2):304-311. 10.1016/j.virol.2008.07.027, 18768193.
44. Steinhauer DA. Role of hemagglutinin cleavage for the pathogenicity of influenza virus. Virology 1999, 258(1):1-20. 10.1006/viro.1999.9716, 10329563.
45. Carinhas N, Bernal V, Yokomizo AY, Carrondo MJ, Oliveira R, Alves PM. Baculovirus production for gene therapy: the role of cell density, multiplicity of infection and medium exchange. Appl Microbiol Biotechnol 2009, 81(6):1041-1049. 10.1007/s00253-008-1727-4, 18923829.
46. He Y, Xu K, Keiner B, Zhou J, Czudai V, Li T, Chen Z, Liu J, Klenk HD, Shu YL, et al. Influenza A virus replication induces cell cycle arrest in G0/G1 phase. J Virol 2010, 84(24):12832-12840. 10.1128/JVI.01216-10, 3004346, 20861262.
47. Aggarwal K, Jing F, Maranga L, Liu J. Bioprocess optimization for cell culture based influenza vaccine production. Vaccine 2011, 29(17):3320-3328. 10.1016/j.vaccine.2011.01.081, 21335031.
48. Mahy BWJ, Kangro HO. Virology Methods Manual 1996, London: Academic Press Limited.
49. Kalbfuss B, Knochlein A, Krober T, Reichl U. Monitoring influenza virus content in vaccine production: precise assays for the quantitation of hemagglutination and neuraminidase activity. Biologicals 2008, 36(3):145-161. 10.1016/j.biologicals.2007.10.002, 18561375.